^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1399P - Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Published date:
09/05/2022
Excerpt:
This was an IRB-approved retrospective study. Eligibility: confirmed diagnosis of mCRPC, first-line treatment with an ARAT (abiraterone or enzalutamide)....Median PFS and OS for AR wt was significantly higher than AR+ pts. In the subgroup analyses median PFS and OS were similar regardless of AR amp or AR mut....In this hypothesis-generating study, pts with mCRPC harboring AR alterations in ctDNA had worse outcomes on first-line ARAT compared to AR wt.